683 Capital Management’s BridgeBio Pharma BBIO Stock Holding History

683 Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,000	Closed	-$153K	–	241
2025 Q4	$153K	Sell	2,000 -298,000	-99%	-$19.6M	0.01%	221
2025 Q3	$15.6M	Sell	300,000 -125,000	-29%	-$6.1M	0.81%	33
2025 Q2	$18.4M	Sell	425,000 -150,000	-26%	-$5.46M	1.21%	20
2025 Q1	$19.9M	Sell	575,000 -60,000	-9%	-$2.02M	1.37%	21
2024 Q4	$17.4M	Buy	635,000 +85,000	+15%	+$2.2M	1.08%	21
2024 Q3	$14M	Buy	550,000 +350,000	+175%	+$9.19M	1.06%	28
2024 Q2	$5.07M	Buy	200,000 +110,000	+122%	+$3.01M	0.38%	61
2024 Q1	$2.78M	Buy	+90,000	New	+$3.06M	0.2%	75

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

683 Capital Management's BBIO Position: Q1 2026 in Review

683 Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 2,000 shares — an estimated $153K sold.

683 Capital Management first reported a position in BBIO in Q1 2024 and held it in 8 quarters. The position peaked at $19.9M in Q1 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

683 Capital Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
683 Capital Management sold 2,000 BridgeBio Pharma shares in Q1 2026, an estimated $153K.
683 Capital Management first reported a position in BridgeBio Pharma in Q1 2024 and held it in 8 quarters.
683 Capital Management's BridgeBio Pharma position peaked at $19.9M in Q1 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.